This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Pharma Stock Roundup: LLY, NVO, PFE Q1 Results, JNJ's New Plan to Resolve Talc Claims
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO), Pfizer (PFE) and AbbVie (ABBV) announce their first-quarter results.
Earnings Season: 3 Companies Boosting Guidance
by Derek Lewis
Earnings season continues to chug along, with results from many companies already delivered. And concerning positivity, all three of these companies' report fit the criteria, lifting outlooks following the results.
ETFs to Buy as Eli Lilly Beats Q1 Earnings, Lifts Outlook
by Sweta Killa
Eli Lilly and Company (LLY) raised its outlook for 2024 on rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro.
Company News for May 1, 2024
by Zacks Equity Research
Companies In The News Are: PYPL, LLY, MMM, GLW.
These 3 Companies Recently Lifted Guidance
by Derek Lewis
Guidance lifts are among the most positive announcements shareholders can hear, injecting confidence in the long-term picture.
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
by Zacks Equity Research
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Eli Lilly (LLY) Q1 Earnings Top, Sales Miss, 2024 View Raised
by Zacks Equity Research
Eli Lilly (LLY) beats first-quarter estimates for earnings but misses the same for sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Earnings Data Deluge
by Zacks Equity Research
Earnings Data Deluge.
Pre-Markets Sell on Last Trading Day of April
by Mark Vickery
Today we close out a month that's likely to be the first negative one since October of last year.
Lilly (LLY) Reports Q1 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Lilly (LLY) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Eli Lilly (LLY) Tops Q1 Earnings Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 1.98% and 0.47%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Markets Up on Tesla, Q1 Earnings; Q1 Beats After the Bell
by Mark Vickery
It's now the third straight day higher going back to Thursday of last week, and recovered from a quick drop into the red.
Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?
by Zacks Equity Research
Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.
Gear Up for Lilly (LLY) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2024.
Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, Merck and AbbVie
by Zacks Equity Research
Eli Lilly, Novo Nordisk, Merck and AbbVie are part of the Zacks Industry Outlook article.
Will Healthcare ETFs Lose Momentum as Q1 Earnings Unfold?
by Sweta Killa
While the healthcare sector is expected to benefit from cutting-edge medicines, new drug approvals, technological advancements, and deal activities, it is expected to witness a modest earnings decline of 5.6% in the first quarter.
4 Large Drug Stocks to Hold on to Amid Industry Challenges
by Kinjel Shah
Drug and biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), Merck (MRK) and AbbVie (ABBV) are worth retaining in one's portfolio.
Analysts Estimate Pfizer (PFE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should Eli Lilly (LLY) Be in Your Portfolio Ahead of Q1 Earnings?
by Kinjel Shah
Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.
Roche (RHHBY) Q1 Hit by Currency Headwinds, Lower COVID-19 Sales
by Zacks Equity Research
Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line suffers due to the appreciation of the Swiss franc against most currencies.
Investors Heavily Search Eli Lilly and Company (LLY): Here is What You Need to Know
by Zacks Equity Research
Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PJP
Eli Lilly (LLY) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eli Lilly (LLY) Advances But Underperforms Market: Key Facts
by Zacks Equity Research
Eli Lilly (LLY) concluded the recent trading session at $731.33, signifying a +0.69% move from its prior day's close.
Pharma Stock Roundup: JNJ's Q1 Results, LLY, ABBV, RHHBY's Successful Study Data
by Kinjel Shah
J&J (JNJ) posts mixed first-quarter 2024 results. Lilly's (LLY) tirzepatide meets key goals in late-stage studies for obstructive sleep apnea.